Literature DB >> 9870204

The success of dietary protein restriction in alkaptonuria patients is age-dependent.

V de Haas1, E C Carbasius Weber, J B de Klerk, H D Bakker, G P Smit, W A Huijbers, M Duran, B T Poll-The.   

Abstract

Alkaptonuria is characterized by an increased urinary excretion of homogentisic acid, pigmentation of cartilage and connective tissues, and ultimately the development of inflammatory arthropathy. Various diets low in protein have been designed to decrease homogentisic acid excretion and to prevent the ochronotic pigmentation and arthritic lesions. However, limited information is available on the long-term beneficial effects of these diets. We reviewed the medical records of 16 patients aged 3-27 years (4 > 18 years) to ascertain the age of diagnosis, growth, development, social behaviour, signs of complications and longitudinal dietary compliance. The diagnosis of alkaptonuria was made at an average age of 1.4 years (2 months-4 years); following the diagnosis all patients were prescribed a diet with a protein content of 1.5 g/kg per day. All patients showed normal growth and development, and no major complications of the disease. Behavioural problems associated with poor dietary compliance emerged as the main problem. Dietary compliance decreased progressively with age. The effect of dietary protein restriction in homogentisic acid excretion was studied by fixing the amounts of protein in the diet at 1 g/kg per day and 3.5-5 g/kg per day during 8 days. Twelve patients, aged 4-27 years, participated in the investigation. Protein restriction resulted in a significantly lower excretion of homogentisic acid in the urine of children younger than 12 years (p < 0.01), whereas this effect was less obvious for adolescent and adult patients. The results suggest that restriction of protein intake may have a beneficial effect on alkaptonuric children; but continuation of this regimen to older age seems questionable and not practical.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870204     DOI: 10.1023/a:1005410416482

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  The nature of the defect in tyrosine metabolism in alcaptonuria.

Authors:  B N LA DU; V G ZANNONI; L LASTER; J E SEEGMILLER
Journal:  J Biol Chem       Date:  1958-01       Impact factor: 5.157

2.  Answer please. Alkaptonuria and ochronosis.

Authors:  S J Bosacco; M Fye; C A Finn
Journal:  Orthopedics       Date:  1991-03       Impact factor: 1.390

Review 3.  The pathology of alkaptonuric ochronosis.

Authors:  J J Gaines
Journal:  Hum Pathol       Date:  1989-01       Impact factor: 3.466

4.  Decreased binding of 14C-homogentisic acid induced by ascorbic acid in connective tissue of rats with experimental alcaptonuria.

Authors:  T J Lustberg; J D Schulman; J E Seegmiller
Journal:  Nature       Date:  1970-11-21       Impact factor: 49.962

5.  aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16.

Authors:  X Montagutelli; A Lalouette; M Coudé; P Kamoun; M Forest; J L Guénet
Journal:  Genomics       Date:  1994-01-01       Impact factor: 5.736

6.  Urinary excretion of 2-methyl-2,3-butanediol and 2,3-pentanediol in patients with disorders of propionate and methylmalonate metabolism.

Authors:  M Duran; D Ketting; L Bruinvis; L Dorland; S K Wadman; J A Bakkeren
Journal:  Clin Chim Acta       Date:  1987-06-15       Impact factor: 3.786

7.  Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy.

Authors:  J A Wolff; B Barshop; W L Nyhan; J Leslie; J E Seegmiller; H Gruber; M Garst; S Winter; K Michals; R Matalon
Journal:  Pediatr Res       Date:  1989-08       Impact factor: 3.756

Review 8.  Ochronosis: a report of a case and a review of literature.

Authors:  Y T Konttinen; V Hoikka; M Landtman; H Saari; S Santavirta; K Metsärinne; J E Seegmiller
Journal:  Clin Exp Rheumatol       Date:  1989 Jul-Aug       Impact factor: 4.473

9.  Homogentisic acid autoxidation and oxygen radical generation: implications for the etiology of alkaptonuric arthritis.

Authors:  J P Martin; B Batkoff
Journal:  Free Radic Biol Med       Date:  1987       Impact factor: 7.376

  9 in total
  8 in total

Review 1.  Alkaptonuria in France: past experience and lessons for the future.

Authors:  Robert Raphael Aquaron
Journal:  J Inherit Metab Dis       Date:  2011-09-17       Impact factor: 4.982

Review 2.  Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria.

Authors:  Jean-Baptiste Arnoux; Kim-Hanh Le Quan Sang; Anais Brassier; Coraline Grisel; Aude Servais; Julien Wippf; Sandrine Dubois; Nicolas Sireau; Chantal Job-Deslandre; Lakshminarayan Ranganath; Pascale de Lonlay
Journal:  J Inherit Metab Dis       Date:  2015-04-10       Impact factor: 4.982

Review 3.  Osteoarthritis? Ochronotic arthritis! A case study and review of the literature.

Authors:  Bao Hui Zhao; Bai Cheng Chen; De Cheng Shao; Qi Zhang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-04-21       Impact factor: 4.342

4.  Ochronosis of the knee with secondary osteoarthritis requiring total knee replacement in a patient with cryptogenic organising pneumonia.

Authors:  Jorrit Jasper; Wieneke Metsaars; Joris Jansen
Journal:  BMJ Case Rep       Date:  2016-05-20

Review 5.  Ochronosis in differential diagnosis of patients with chronic backache: a review of the literature.

Authors:  Erhan Capkin; Murat Karkucak; Savaş Yayli; Münevver Serdaroğlu; Mehmet Tosun
Journal:  Rheumatol Int       Date:  2007-06-13       Impact factor: 2.631

Review 6.  Alkaptonuria.

Authors:  Jemma B Mistry; Marwan Bukhari; Adam M Taylor
Journal:  Rare Dis       Date:  2013-12-18

7.  Alkaptonuria and Pompe disease in one patient: metabolic and molecular analysis.

Authors:  Mohammad Zouheir Habbal; Tarek Bou Assi; Hicham Mansour
Journal:  BMJ Case Rep       Date:  2013-04-29

8.  Towards a Precision Medicine Approach Based on Machine Learning for Tailoring Medical Treatment in Alkaptonuria.

Authors:  Ottavia Spiga; Vittoria Cicaloni; Anna Visibelli; Alessandro Davoli; Maria Ausilia Paparo; Maurizio Orlandini; Barbara Vecchi; Annalisa Santucci
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.